Taika Capital, LP Biogen Inc. Transaction History

Taika Capital, LP

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$256.56 - $292.34 $1.85 Million - $2.11 Million	7,205 Added 101.48%	14,305 $3.98 Million
Q4 2022 Feb 09, 2023	BUY	$252.44 - $306.72 $860,315 - $1.05 Million	3,408 Added 92.31%	7,100 $1.97 Million
Q3 2022 Nov 14, 2022	BUY	$194.69 - $268.46 $663,503 - $914,911	3,408 Added 92.31%	7,100 $1.9 Million
Q3 2022 Nov 14, 2022	BUY	$194.69 - $268.46 $718,795 - $991,154	3,692 New	3,692 $986,000

1,018

128M

1.22M

1.4M

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $25B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

Get notified when there are updates to the investment portfolio of Taika Capital, LP, based on Form 13F filings with the SEC.

Stay updated on Taika Capital, LP with notifications on news.